Compare ADMA Biologics Inc (ADMA) vs InMode Ltd (INMD) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

INMD trades at $14.60, down 1.35% on the day, with mixed technical signals showing bullish moving averages but neutral oscillators. The company maintains strong profitability with 77.84% gross margins and 23.27% net income margins, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited buyout proposal at $16.20 per share and multiple securities fraud investigations announced in early July 2026.

The stock appears undervalued with a P/E of 10.81 and EV/EBITDA of 3.81, but faces near-term headwinds from legal investigations and earnings volatility. Analyst consensus sits at Hold with a $16.50 price target, representing 13% upside potential from current levels, though the ongoing legal scrutiny creates uncertainty for investors.